175 related articles for article (PubMed ID: 22418076)
1. New times, new trends for ethionamide: In vitro evaluation of drug-loaded thermally carbonized porous silicon microparticles.
Vale N; Mäkilä E; Salonen J; Gomes P; Hirvonen J; Santos HA
Eur J Pharm Biopharm; 2012 Jun; 81(2):314-23. PubMed ID: 22418076
[TBL] [Abstract][Full Text] [Related]
2. Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis.
Vale N; Correia A; Silva S; Figueiredo P; Mäkilä E; Salonen J; Hirvonen J; Pedrosa J; Santos HA; Fraga A
Bioorg Med Chem Lett; 2017 Feb; 27(3):403-405. PubMed ID: 28057421
[TBL] [Abstract][Full Text] [Related]
3. Enhanced in vitro permeation of furosemide loaded into thermally carbonized mesoporous silicon (TCPSi) microparticles.
Kaukonen AM; Laitinen L; Salonen J; Tuura J; Heikkilä T; Limnell T; Hirvonen J; Lehto VP
Eur J Pharm Biopharm; 2007 Jun; 66(3):348-56. PubMed ID: 17240128
[TBL] [Abstract][Full Text] [Related]
4. Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles.
Limnell T; Riikonen J; Salonen J; Kaukonen AM; Laitinen L; Hirvonen J; Lehto VP
Int J Pharm; 2007 Oct; 343(1-2):141-7. PubMed ID: 17600644
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity.
Huotari A; Xu W; Mönkäre J; Kovalainen M; Herzig KH; Lehto VP; Järvinen K
Int J Pharm; 2013 Sep; 454(1):67-73. PubMed ID: 23834832
[TBL] [Abstract][Full Text] [Related]
7. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole.
Kinnari P; Mäkilä E; Heikkilä T; Salonen J; Hirvonen J; Santos HA
Int J Pharm; 2011 Jul; 414(1-2):148-56. PubMed ID: 21601623
[TBL] [Abstract][Full Text] [Related]
8. In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size.
Santos HA; Riikonen J; Salonen J; Mäkilä E; Heikkilä T; Laaksonen T; Peltonen L; Lehto VP; Hirvonen J
Acta Biomater; 2010 Jul; 6(7):2721-31. PubMed ID: 20036766
[TBL] [Abstract][Full Text] [Related]
9. Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles.
Bimbo LM; Mäkilä E; Raula J; Laaksonen T; Laaksonen P; Strommer K; Kauppinen EI; Salonen J; Linder MB; Hirvonen J; Santos HA
Biomaterials; 2011 Dec; 32(34):9089-99. PubMed ID: 21864895
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis.
Kumar G; Sharma S; Shafiq N; Pandhi P; Khuller GK; Malhotra S
Drug Deliv; 2011 Jan; 18(1):65-73. PubMed ID: 20735202
[TBL] [Abstract][Full Text] [Related]
11. Tablet preformulations of indomethacin-loaded mesoporous silicon microparticles.
Tahvanainen M; Rotko T; Mäkilä E; Santos HA; Neves D; Laaksonen T; Kallonen A; Hämäläinen K; Peura M; Serimaa R; Salonen J; Hirvonen J; Peltonen L
Int J Pharm; 2012 Jan; 422(1-2):125-31. PubMed ID: 22063301
[TBL] [Abstract][Full Text] [Related]
12. In vitro assessment of biopolymer-modified porous silicon microparticles for wound healing applications.
Mori M; Almeida PV; Cola M; Anselmi G; Mäkilä E; Correia A; Salonen J; Hirvonen J; Caramella C; Santos HA
Eur J Pharm Biopharm; 2014 Nov; 88(3):635-42. PubMed ID: 25305585
[TBL] [Abstract][Full Text] [Related]
13. Cellular interactions of surface modified nanoporous silicon particles.
Bimbo LM; Sarparanta M; Mäkilä E; Laaksonen T; Laaksonen P; Salonen J; Linder MB; Hirvonen J; Airaksinen AJ; Santos HA
Nanoscale; 2012 May; 4(10):3184-92. PubMed ID: 22508528
[TBL] [Abstract][Full Text] [Related]
14. Systematic in vitro and in vivo study on porous silicon to improve the oral bioavailability of celecoxib.
Riikonen J; Correia A; Kovalainen M; Näkki S; Lehtonen M; Leppänen J; Rantanen J; Xu W; Araújo F; Hirvonen J; Järvinen K; Santos HA; Lehto VP
Biomaterials; 2015 Jun; 52():44-55. PubMed ID: 25818412
[TBL] [Abstract][Full Text] [Related]
15. Failure of MTT as a toxicity testing agent for mesoporous silicon microparticles.
Laaksonen T; Santos H; Vihola H; Salonen J; Riikonen J; Heikkilä T; Peltonen L; Kumar N; Murzin DY; Lehto VP; Hirvonen J
Chem Res Toxicol; 2007 Dec; 20(12):1913-8. PubMed ID: 17990852
[TBL] [Abstract][Full Text] [Related]
16. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs.
Salonen J; Laitinen L; Kaukonen AM; Tuura J; Björkqvist M; Heikkilä T; Vähä-Heikkilä K; Hirvonen J; Lehto VP
J Control Release; 2005 Nov; 108(2-3):362-74. PubMed ID: 16169628
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
Costa-Gouveia J; Pancani E; Jouny S; Machelart A; Delorme V; Salzano G; Iantomasi R; Piveteau C; Queval CJ; Song OR; Flipo M; Deprez B; Saint-André JP; Hureaux J; Majlessi L; Willand N; Baulard A; Brodin P; Gref R
Sci Rep; 2017 Jul; 7(1):5390. PubMed ID: 28710351
[TBL] [Abstract][Full Text] [Related]
18. Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers.
Shrestha N; Shahbazi MA; Araújo F; Zhang H; Mäkilä EM; Kauppila J; Sarmento B; Salonen JJ; Hirvonen JT; Santos HA
Biomaterials; 2014 Aug; 35(25):7172-9. PubMed ID: 24844163
[TBL] [Abstract][Full Text] [Related]
19. Controlled Dissolution of Griseofulvin Solid Dispersions from Electrosprayed Enteric Polymer Micromatrix Particles: Physicochemical Characterization and in Vitro Evaluation.
Roine J; Kaasalainen M; Peurla M; Correia A; Araújo F; Santos HA; Murtomaa M; Salonen J
Mol Pharm; 2015 Jul; 12(7):2254-64. PubMed ID: 26035734
[TBL] [Abstract][Full Text] [Related]
20. Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs.
Zhang Y; Wang J; Bai X; Jiang T; Zhang Q; Wang S
Mol Pharm; 2012 Mar; 9(3):505-13. PubMed ID: 22217205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
